Novo presents detailed CV data for Victoza

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) reported detailed data from the LEADER CV outcomes trial comparing diabetes drug Victoza liraglutide plus standard of care vs. placebo plus SOC. In March, the company said

Read the full 322 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE